TGM2 and celiac disease: The Cure Huntington’s Disease Initiative Foundation (CHDI) and Evotec are developing a different class of Michael acceptor compounds targeting the TGase 2 active site for the treatment of diseases such as neurodegenerative diseases and celiac disease [23].